SQZ Biotechnologies Company

OTCPK:SQZB Stock Report

Market Cap: US$707.8k

SQZ Biotechnologies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for SQZ Biotechnologies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth24.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Jun 26

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Jan 05

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 09

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

SQZ Biotechnologies press release (NYSE:SQZ): Q3 GAAP EPS of -$0.77 beats by $0.06. Revenue of $3.5M (-27.1% Y/Y) misses by $0.76M. Company had cash and cash equivalents of $84.2 million and anticipates this will be sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2023
Seeking Alpha • Oct 20

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

SQZ Biotechnologies (NYSE:SQZ), a biotech focused on cell therapies, added ~5% pre-market Thursday after H.C. Wainwright launched its coverage with a Buy rating and a $5 target highlighting the company’s Cell Squeeze technology platform. The analyst Emily Bodnar notes that the Cell Squeeze technology is designed to address many shortcomings in current cell therapy platforms as it doesn’t require lymphodepletion, allows flexibility of cell type and cargo, and faster production while maintaining cell health and function. The Antigen Presenting Cell (APC) platform, SQZ’s most advanced cell therapy technology is a collaboration with Roche (OTCQX:RHHBY) (OTCQX:RHHBF) which validates its potential, the analyst argued. Bodnar sees multiple catalysts ahead for SQZ before year-end as the company expects to report updated data for the APC program and initial data for eAPC and AAC programs in Q4 2022. Early this year, the FDA granted Fast Track designation for SQZ’s APC clinical candidate, SQZ-PBMC-HPV, for HPV16+ advanced or metastatic tumors.
Analysis Article • Aug 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 04

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

SQZ Biotechnologies press release (NYSE:SQZ): Q2 GAAP EPS of -$0.78 misses by $0.01. Revenue of $3.22M (-29.1% Y/Y) misses by $0.97M. “We are excited by meaningful progress in our clinical trials and also the receipt of FDA Fast Track Designation for our APC clinical candidate across HPV16+ tumors,” said Armon Sharei, Ph.D., CEO and Founder at SQZ Biotechnologies. “We also highlighted the progress in developing our Point-of-Care manufacturing system which supports our long-term vision to enable broad accessibility of cell therapies. Finally, I am delighted by the addition of our newest senior team member, Dr. Marshelle Smith Warren as our Chief Medical Officer, and the elevation of Micah Zajic to Chief Financial Officer.”
Seeking Alpha • Jul 11

SQZ Biotechnologies names business chief as CFO

SQZ Biotechnologies (NYSE:SQZ) announced Monday the promotion of Micah Zajic to the role of company's chief financial officer, effective immediately. Zajic has served as the company’s chief business officer since October 2020 and brings nearly two decades of biotechnology and capital markets experience to the role. Prior to joining SQZ, he led corporate development activities at MeiraGTx Holdings including execution of a collaboration agreement with Janssen Pharmaceuticals. Earlier: SQZ Biotechnologies names Marshelle Smith Warren as chief medical officer
Analysis Article • May 17

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

Market forces rained on the parade of SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders today, when the analysts...
Analysis Article • May 02

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 11

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jul 30

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 16

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Mar 25

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

The analysts covering SQZ Biotechnologies Company ( NYSE:SQZ ) delivered a dose of negativity to shareholders today, by...
Analysis Article • Mar 20

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

SQZ Biotechnologies Company ( NYSE:SQZ ) came out with its full-year results last week, and we wanted to see how the...
Analysis Article • Feb 01

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SQZ Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:SQZB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202312-72-75-74N/A
6/30/202316-71-82-82N/A
3/31/202319-76-87-87N/A
12/31/202221-79-84-84N/A
9/30/202222-78-84-84N/A
6/30/202223-78-83-83N/A
3/31/202225-74-83-82N/A
12/31/202127-69-83-82N/A
9/30/202117-75-81-80N/A
6/30/202119-64-75-75N/A
3/31/202120-55-68-67N/A
12/31/202021-51-44-43N/A
9/30/202025-43-35-33N/A
6/30/202023-39-35-33N/A
3/31/202021-37-21-20N/A
12/31/201920-32-36-33N/A
12/31/201813-202021N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SQZB's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if SQZB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SQZB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SQZB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SQZB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SQZB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 10:41
End of Day Share Price 2026/06/05 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SQZ Biotechnologies Company is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Leah Rush CannBrookline Capital Markets
Thomas ShraderBTIG